HomeNVAX • NASDAQ
add
Novavax Inc
Nakaraang pagsara
$7.51
Sakop ng araw
$7.51 - $7.68
Sakop ng taon
$5.01 - $11.50
Market cap
1.24B USD
Average na Volume
4.24M
P/E ratio
3.34
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 239.24M | -42.42% |
Gastos sa pagpapatakbo | 53.28M | -53.23% |
Net na kita | 106.51M | -34.41% |
Net profit margin | 44.52 | 13.92% |
Kita sa bawat share | 0.62 | -37.37% |
EBITDA | 113.23M | -34.63% |
Aktuwal na % ng binabayarang buwis | 0.88% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 612.30M | -41.66% |
Kabuuang asset | 1.34B | -26.51% |
Kabuuang sagutin | 1.30B | -42.28% |
Kabuuang equity | 37.62M | — |
Natitirang share | 162.42M | — |
Presyo para makapag-book | 32.65 | — |
Return on assets | 20.09% | — |
Return on capital | 126.06% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 106.51M | -34.41% |
Cash mula sa mga operasyon | -127.46M | -140.56% |
Cash mula sa pag-invest | 111.10M | 129.81% |
Cash mula sa financing | -1.04M | -100.40% |
Net change in cash | -9.50M | -104.76% |
Malayang cash flow | -124.92M | -122.15% |
Tungkol
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Itinatag
1987
Headquarters
Website
Mga Empleyado
952
